No bikes were involved in these biotech offerings

A trio of biotech IPOs, all focused on cancer, are headed down the pike this week: Peloton Therapeutics, Ideaya Biosciences, and Bicycle Therapeutics. 

Peloton’s lead candidate will target advanced kidney cancer; the company expects to kick off a Phase 3 trial later this year, using technology that regulates how oxygen is used in the body. The company, which has no relation to the eponymous stationary bike, hopes to raise about $160 million.

Bicycle Therapeutics, which also is not remotely linked to wheel-based transportation, aims to raise $69 million. The biotech takes its name from the synthetic protein it's developing; it's in the shape of two loops, like a bicycle’s wheels. 

The third company, Ideaya, licensed a Novartis eye cancer drug and now has all future clinical development and commercial rights to it. Looks like it’s in the market to raise about $75 million in its offering.